Friday, FDA’s Division of Drug Marketing, Advertising and Communications posted 14 untitled letters (enforcement actions) on its website that cited 14 different companies for inappropriate sponsored links/search results place on search engines like Google or Yahoo! I would not ordinarily discuss this issue on GoodReprintPractices.com, but reprint dissemination is only a myopic picture of my [...]
Among the more useful things I’ve always found in my travels as a regulatory and compliance professional are surveys of peers or interested parties related to the things I’m interested in. GoodReprintPractices.com has added a polling function and I ask all relevant users to participate as they visit the site. Hopefully, this will help me [...]
I took it upon myself to mix it up with John Mack at the Pharma Marketing Blogs. I got the “John Mack treatment.” I like John’s attitude and attentiveness to the pharma world. My diatribes and appearances are here and here. Read the comments. Nothing here about GoodReprintPractices.com. Just some regulatory discussion.
JM (John Murray not [...]
While there are fears, accusations, and criticism that the final Good Reprint Practices guidance document will allow drug and device companies to now “promote off-label uses,” this is not at all the case. Such views represent a fundamental misunderstanding of the plain language of the final guidance document, a fundamental misunderstanding of the extent of [...]
Theme Song In Dminor Click here.
Every good blog deserves a theme song. This is ours. Its called Theme Song in Dminor. I really find that Dminor is the saddest of all keys. I believe the state of understanding about the practice of reprint dissemination is somewhat sad from many angles, both [...]